Publications

Original Research from ISCHEMIA

Kataoka A, Scherrer-Crosbie M., Senior R, Gosselin G, Phaneuf D, Guzman G, Perna G, Lara A, Kedev S, Mortara A, El-Hajjar M, Shaw LJ, Reynolds HR, Picard MH. The value of core lab stress echocardiography interpretations: observations from the ISCHEMIA trial. Cardiovasc Ultrasound. 2015;13:47. Link

Kataoka A, Scherrer-Crosbie M, Dajani KA, Garceau P, Hastings JL, Kohn JA, Srbinovska-Kostovska E, Poggio D, Saric M, Senior R, Sokhon K, Shaw L, Reynolds H, Picard MH. Transient ischemic dilatation during stress echocardiography: an additional marker of significant myocardial ischemia. Echocardiography. 2016 Apr 3. doi: 10.1111/echo.13222. Link

Bagai A, Alexander KP, Berger JS, Senior R, Sajeev C, Pracon R, Mavromatis K, Lopez-Sendón JL, Gosselin G, Diaz A, Perna G, Drozdz J, Humen D, Petrauskiene B, Cheema AN, Phaneuf D, Banerjee S, Miller TD, Kedev S, Schuchlenz H, Stone GW, Goodman SG, Mahaffey KW, Jaffe AS, Rosenberg YD, Bangalore S, Newby LK, Maron DJ, Hochman JS, Chaitman BR. The use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. Am Heart J. 2017 Aug;190:135-139. doi: 10.1016/j.ahj.2017.04.016. Epub 2017 Jun 16. PMID:28760208. Link

ISCHEMIA Trial Research Group, MaronDJ, Hochman JS, O'Brien SM, Reynolds HR, Boden WE, Stone GW, Bangaore S, Spertus JA, Mark DB, Alexander KP, Shaw L, Berger JS, Ferguson TB Jr, William DO, Harrington RA, Rosenberg Y. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. Am Heart J. 2018 Apr 21;201:124-135. doi: 10.1016/j.ahj.2018.04.011. [Epub ahead of print] PMID:29778671. Link

Hochman JS, Maron DJ. Letter by Hochman and Maron regarding article, "'Faith Healing' and 'Subtraction Anxiety' in unblinded trials of procedures: Lessons from DEFER and FAME-2 for end points in the ISCHEMIA trial." Circ Cardiovasc Qual Outcomes 2018 Apr;11(4):e004742. doi: 10.1161/CIRCOUTCOMES.118.004742. Link

Bangalore S, Maron DJ, Reynolds HR, Stone GW, O'Brien SM, PhD; ALexander KP, Hochman JS. ISCHEMIA: Establishing the primary end point. Circ Cardiovasc Qual Outcomes. 2018 May;11 (5):e004791. doi:10.1161/CIRCOUTCOMES. 118.004791. Noabstract available. PMID: 29752391. Link

Bangalore S, Maron DJ, Fleg JL, O'Brien SM, Herzog CA, Stone GW, Mark DB, Spertus JA, Alexander KP, Sidhu MS, Chertow GM, Boden WE, Hochman JS; ISCHEMIA-CKD Research Group. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches-Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design. Am Heart J 2018;205:42-52. Link

Maron DJ, Harrington RA, Hochman JS. Planning and conducting the ISCHEMIA trial: Setting the record straight. Circulation 2018;138:1384–1386. Link

Hochman JS, Reynolds HR, Bangalore S, O'Brien S, Alexander K, Senior R, Boden W, Stone G, Goodman S, Lopes R, Lopez-Sendon J, White H, Maggioni A, Shaw L, Min J, Picard M, Berman D, Chaitman B, Mark D, Spertus J, Cyr D, Bhargava B, Ruzyllo W, Wander G, Chernyavskiy A, Rosenberg Y, Maron DJ. Baseline characteristics of participants in the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA). Available online. JAMA Cardiology 2019. Link

Papers by ISCHEMIA Study Investigators

Shaw LJ, Xie JX, Phillips LM, Goyal A, Reynolds HR, Berman DS, Picard MH, Bhargava B, Devlin G, Chairtman BR. Optimising diagnostic accuracy with the exercise ECG: opportunities for women and men with stable ischaemic heart disease. Heart Asia 2016; 8:1-7. Link

Ohman EM. Chronic Stable Angina. N Engl J Med 2016; 374:1167-1176. Link

Stone GW, Hochman JS, Williams DO, Boden WE, Ferguson TB Jr., Harrington RA, Maron DJ. Medical therapy with versus without revascularization in stable patients with moderate and severe ischemia: the case for community equipoise. J Am Coll Cardiol 2016;67:81-99. Link

Cheng-Torres, KA, Desai KP, Sidhu MS, Maron DJ, Boden WE. Conservative versus invasive stable ischemic heart disease management strategies: what do we plan to learn from the ISCHEMIA trial? Future Cardiol 2016;12:35-44. Link

Bangalore S, Maron DJ, Hochman JS. Evidence-based management of stable ischemic heart disease: challenges and confusion. JAMA 2015; 314:1917-1918. Link

Torosoff MT, Sidhu MS, Desai KP, Fein SA, Boden WE. Revascularization options in stable coronary artery disease: it is not how to revascularize, it is whether and when to revascularize. J Comp Eff Res. 2015 Sep;4(5):505-14. Link 

Maron DJ, Boden WE. Why optimal medical therapy should be a universal standard of care. J Am Coll Cardiol 2015;66:774-6. Link

Sidhu MS, Boden WE. The continued importance of optimal medical therapy with or without revascularization in diabetic patients with coronary artery disease. Trends Cardiovasc Med. 2015 Oct; 25(7):632-4. Link

Gibbons RJ, Miller TD. Should extensive myocardial ischaemia prompt revascularization to improve outcomes in chronic coronary artery disease? Eur Heart J 2015;36:2281-7. Link

Mody P, Sidhu MS, Brilakis ES, Sacco JD, Banerjee S, Boden WE. Anti-Anginal Agents for the Management of Stable Ischemic Heart Disease: A Review. Cardiol Rev. 2015 Aug 4. Link

Reynolds HR, Picard MH, Hochman JS. Does ischemia burden in stable coronary artery disease effectively identify revascularization candidates? Ischemia burden in stable coronary artery disease does not effectively identify revascularization candidates. Circ Cardiov Imaging 2015 May; 8(5): discussion p 9. Link

Shaw LJ, Berman DS,  Picard MH, Friedrich MG,  Kwong RY, Stone GW,  Senior R,  Min JK,  Hachamovitch R,  Scherrer-Crosbie M,  Mieres JH,  Marwick TH,  Phillips LM, Chaudhry FA,  Pellikka PA,  Slomka P, Arai AE,  Iskandrian AE,  Bateman TM, Heller GV,  Miller TD,  Nagel E,  Goyal A, Borges-Neto S, Boden WE,  Reynolds HR, Hochman JS, Maron DJ,  Douglas PS. Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. JACC Cardiovasc Imaging 2014;7:593-604. Link

Maron DJ, Boden WE. As REGARDS treatment goal attainment compared with COURAGE: the perfect should not be the enemy of the good. J Am Coll Cardiol 2014;63:1634-5. Link

Padala SK; Sidhu MS; Boden WE.  Stable Ischemic Heart Disease. (Ed.) Pan Vascular Medicine, 2014. Springer-Verlag Berlin Heidelberg. Link

Desai KP, Sidhu MS, Boden WE. Evaluation of the stable coronary artery disease patient: anatomy trumps physiology. Trends Cardiovasc Med. 2014 Nov;24(8):332-40. Link

Padala S, Sidhu MS, Boden WE. Evolving Concepts in Defining Optimal Strategies for the Management of Patients with Stable Ischemic Heart Disease. Medicographia. 2014 May; 36:45-54. Link

Chan P, Williams DO. Coronary revascularization for myocardial ischemia. Circ Cardiovasc Interv 2013; 6:123-4. Link

Fassa A-A, Wijns W, Kolh P, Steg PG. Benefit of revascularization for stable ischaemic heart disease: the jury is still out. Eur Heart J 2013; 34 (21):1534-8. Link 

Torosoff MT, Fein SA, Boden WE. Does the potential overuse of routine post PCI stress testing and revascularization inspire courage to embrace more evidence-based decision making? Circ Cardiovasc Imaging. 2013 Jan 1;6(1):2-5. Link

Maron DJ, Ting HH. In mildly symptomatic patients, should an invasive strategy with catheterization and revascularization be routinely undertaken? In mildly symptomatic patients, an invasive strategy with catheterization and revascularization should not be routinely undertaken. Circ Cardiovasc Interv 2013; 6:114-121. Link

Maron DJ, Hochman JS. Revascularization for silent ischemia? : Another piece of the puzzle. J Am Coll Cardiol 2013; 61:1624–5. Link

Mecklai A, Bangalore S, Hochman JS. How and when to decide on revascularization in stable ischemic heart disease. Curr Treat Options Cardiovasc Med 2013; 15:79-92. Link 

Hambrecht R, Berra K, Calfas KJ. Managing your angina symptoms with nitroglycerin: what about exercise? Circulation 2013; 127:e642-e645. Link 

Sidhu MS, Boden WE. Asymptomatic CAD & Silent Ischemia: Roles of Stress Testing, Myocardial Imaging, Optimal Medical Therapy, and Myocardial Revascularization in Clinical Decision Support. July 2013.  Decision Support in Medicine, LLC. Wilmington, DE. Link

Sidhu MS, Boden WE. Optimal medical therapy vs. revascularization on long-term LV function. Eur Heart J. 2013 Nov; 34(43):3339-41. Link

Torosoff MT, Sidhu MS, Boden WE. Impact of myocardial ischemia on myocardial revascularization in stable ischemic heart disease. Lessons from the COURAGE & FAME 2 trials. Herz. 2013 Jun;38(4):382-6. Link

Sidhu MS, Boden WE. Does Revascularization Work? Heart and Metabolism. Review. (March 2013) Volume Number 58:10-14. Link

Phillips LM, Hachamovitch R, Berman DS, Iskandrian AE, Min JK, Picard MH, Kwong RY, Friedrich MG, Scherrer-Crosbie M, Hayes SW, Sharir T, Gosselin G, Mazzanti M, Senior R, Beanlands R, Smanio P, Goyal A, Al-Mallah M, Reynolds H, Stone GW, Maron DJ, Shaw LJ. Lessons learned from MPI and physiologic testing in randomized trials of stable ischemic heart disease: COURAGE, BARI 2D, FAME, and ISCHEMIA. J Nucl Cardiol 2013;20:969-75. Link

Maron DJ, Stone GW, Berman DS, Mancini GBJ, Scott TA, Byrne DW, Harrell FE, Shaw LJ, Hachamovitch R, Boden WE, Weintraub WS, Spertus JA. Is cardiac catheterization necessary prior to initial management of patients with stable ischemic heart disease? Results from a web-based survey of cardiologists. Am Heart J 2011;162:1034-1043. Link

 

Papers Relevant to ISCHEMIA

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018 Nov 29;379(22):2097-2107. Link

Kufner S, Joner M, Thannheimer A, Hoppmann P, Ibrahim T, Mayer K, Cassese S, Laugwitz KL, Schunkert H, Kastrati A, Byrne RA. Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease results from the isar-test 4 randomized trial. Circulation. 2018 Nov 11. doi: 10.1161/CIRCULATIONAHA.118.038065. Link

Zenati MA, Bhatt DL, Bakaeen FG, Stock EM, Biswas K, Gaziano JM, Kelly RF, Tseng EE, Bitondo J, Quin JA, Almassi GH, Haime M, Hattler B, DeMatt E, Scrymgeour A, Huang GD. Randomized Trial of Endoscopic or Open Vein-Graft Harvesting for Coronary-Artery Bypass. N Engl J Med. 2018 Nov 11. doi: 10.1056/NEJMoa1812390. Link

Bhatt DL, Steg PG, Miller, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2018 Nov 10. doi: 10.1056/NEJMoa1812792. Link

Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2018 Nov 10. doi: 10.1056/NEJMoa1809798. Link

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018 Nov 10. doi: 10.1056/NEJMoa1812389. Link

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2018 Nov 8. pii: S0735-1097(18)39034-X. Link

Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, Hamza TH, Shah B, Stefanini GG, Sidhu MS, Tanguay JF, Ramanathan K, Sharma SK, French J, Hueb W, Cohen DJ, Fuster V. Long-term survival following multivessel revascularization in patients with diabetes (freedom follow-on study). J Am Coll Cardiol. 2018 Nov 1. pii: S0735-1097(18)38994-0. Link

Bhagirath VC, Eikelboom JW, Anand SS. Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS. Future Cardiol. 2018 Nov;14(6):443-453. doi: 10.2217/fca-2018-0059. Link

Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, George SM, Olson RD. The physical activity guidelines for Americans. JAMA. 2018 Nov 20;320(19):2020-2028. Link

Sedlis SP, Hartigan PM, Teo KK, Maron DJ, Spertus JA, John Mancini GB, Kostuk W, Chaitman BR, Berman D, Lorin JD, Dada M, Weintraub WS, Boden WE. Effect of PCI on long-term survival in patients with stable ischemic heart disease. N Engl J Med 2015; 373:1937-1946. Link

Mancini GB, Hartigan PM, Shaw LJ, Berman DS, Hayes SW, Bates ER, Maron DJ, Teo K, Sedlis SP, Chaitman BR, Weintraub WS, Spertus JA, Kostuk WJ, Dada M, Booth DC, Boden WE. Predicting outcome in the COURAGE trial coronary anatomy versus ischemia. JACC Cardiovasc Interv 2014; 2:195-201. Link

Spertus JA, Maron DJ, Cohen DJ, Kolm P, Hartigan P, Weintraub WS, Berman DS, Teo KK, Shaw LJ, Sedlis SP, Knudtson M, Aslan M, Dada M, Boden WE, Mancini GB. Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) Trial. Circ Cardiovasc Qual Outcomes 2013; 6:409-18. Link

Hachamovitch R, Nutter B, Hlatky MA, Shaw LJ, Ridner ML, Dorbala S, Beanlands RS, Chow BJ, Branscomb E, Chareonthaitawee P, Weigold WG, Voros S, Abbara S, Yasuda T, Jacobs JE, Lesser J, Berman DS, Thomson LE, Raman S, Heller GV, Schussheim A, Brunken R, Williams KA, Farkas S, Delbeke D, Schoepf UJ, Reichek N, Rabinowitz S, Sigman SR, Patterson R, Corn CR, White R, Kazerooni E, Corbett J, Bokhari S, Machac J, Guarneri E, Borges-Neto S, Millstine JW, Caldwell J, Arrighi J, Hoffmann U, Budoff M, Lima J, Johnson JR, Johnson B, Gaber M, Williams JA, Foster C, Hainer J, Di Carli MF. Patient management after noninvasive cardiac imaging results from SPARC (Study of myocardial perfusion and coronary anatomy imaging roles in coronary artery disease). J Am Coll Cardiol 2012; 59:462-474. Link

Shaw LJ, Weintraub WS, Maron DJ, Hartigan PM, Hachamovitch R, Min JK, Dada M, Mancini GB, Hayes SW, O’Rourke RA, Spertus JA, Kostuk W, Gosselin G, Chaitman BR, Knudtson M, Friedman J, Slomka P, Germano G, Bates ER, Teo KK, Boden WE, Berman DS. Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. Am Heart J 2012; 164:243-50. Link

Bruyne BD, Pijls NHJ, Kalesan B, Barbato E, Tonino PAL, Piroth Z, Jagic N, Möbius-Winkler S, Rioufol G, Witt N, Kala P, MacCarthy P, Engström T, Oldroyd KG, Mavromatis K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson JB, Jüni P, and Fearon WF. Fractional Flow Reserve–Guided PCI versus Medical Therapy in Stable Coronary Disease. N Engl J Med 2012 Sept; 367:991-1001. Link

BARI2D Study Group. A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. N Engl J Med 2009 Jun; 360:2503-2515 June. Link 

Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, John Mancini GB, Weintraub WS. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356:1503-1516. Link